CLINICAL EVALUATION OF NOVEL BRONCHODILATOR THERAPIES IN SEVERE ASTHMA MANAGEMENT
Journal of Biosciences and Innovations · 30.06.2026 · 3 (01) · 1-16
DOI: 10.64037/jbi.01.33 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biosciences and Innovations, online erschienen am 30.06.2026. Verfasst von Naveed Inayat. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Severe asthma remains a clinical problem and not all of the patients can be managed on high-dose of inhaled corticosteroids and long-acting 2-agonists. Phosphodiesterase inhibitors are anti-inflammatory, bronchodilatory as well as oral PDE4 inhibitors such as roflumilast are hampered by the systemic adverse gastrointestinal system. PDE4 and dual PDE3/4 inhibitors inhaled represent a new alternative to enhance the therapeutic index in order to deliver the drug to the airways which have the least contact with the systemic circulation. The paper objectives were a quantitative systems pharmacology model which included compartmental pharmacokinetic model, pharmacodynamic model and analysis of clinical trial data on a meta-analysis basis to compare the effect and safety profile of inhaled tanimilast (selective PDE4 inhibitor), inhaled ensifentrine (dual Ensifentrine, too, has the largest anti-inflammatory effects on TNF- Above all ensifentrine had the highest therapeutic index (34.7) and the projected rate of gastrointestinal adverse events was merely 6.1 as compared to the rate of roflumilast (32.4). The meta-analysis of clinical efficacy showed that ensifentrine was the agent that generated the best improvement in trough FEV1 (0.29 L) and the biggest change in the annualized rate of exacerbation (rate ratio 0.57). Ensifentrine exhibited the greatest effects of anti-remodeling with 26.7% decreased subepithelial fibrosis, and 38.9% decreased TGF-b1 expression. Ensifentrine lung-targeted inhaled dual PDE3/4 inhibition is synergistic with bronchodilation, with a longer-lasting anti-inflammatory profile and significant improvement in its safety profile, than PDE4 selective inhibition. The results justify ensifentrine as a game-changer in the uncontrolled, severe asthma treatment, and the improved effect and increased tolerability are anticipated.
Zitieren
APA
Inayat, N. (2026). CLINICAL EVALUATION OF NOVEL BRONCHODILATOR THERAPIES IN SEVERE ASTHMA MANAGEMENT. Journal of Biosciences and Innovations, 3(01), 1-16. https://doi.org/10.64037/jbi.01.33
Vancouver
Inayat N. CLINICAL EVALUATION OF NOVEL BRONCHODILATOR THERAPIES IN SEVERE ASTHMA MANAGEMENT. Journal of Biosciences and Innovations. 2026;3(01):1-16. doi:10.64037/jbi.01.33
BibTeX
@article{Inayat2026,
author = {Inayat, Naveed},
title = {CLINICAL EVALUATION OF NOVEL BRONCHODILATOR THERAPIES IN SEVERE ASTHMA MANAGEMENT},
journal = {Journal of Biosciences and Innovations},
year = {2026},
volume = {3},
number = {01},
pages = {1--16},
doi = {10.64037/jbi.01.33}
}
EUVIMED